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Abstract
Persistently low white blood cell count (WBC) and neutrophil count is a well-described phenomenon in persons of African
ancestry, whose etiology remains unknown. We recently used admixture mapping to identify an approximately 1-megabase
region on chromosome 1, where ancestry status (African or European) almost entirely accounted for the difference in WBC
between African Americans and European Americans. To identify the specific genetic change responsible for this
association, we analyzed genotype and phenotype data from 6,005 African Americans from the Jackson Heart Study (JHS),
the Health, Aging and Body Composition (Health ABC) Study, and the Atherosclerosis Risk in Communities (ARIC) Study. We
demonstrate that the causal variant must be at least 91% different in frequency between West Africans and European
Americans. An excellent candidate is the Duffy Null polymorphism (SNP rs2814778 at chromosome 1q23.2), which is the
only polymorphism in the region known to be so differentiated in frequency and is already known to protect against
Plasmodium vivax malaria. We confirm that rs2814778 is predictive of WBC and neutrophil count in African Americans above
beyond the previously described admixture association (P=3.8610
25), establishing a novel phenotype for this genetic
variant.
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A large proportion of healthy African Americans have been
observed to have a white blood cell count (WBC) that is
persistently lower than the normal range defined for individuals
of European ancestry [1–5]. This condition, called ‘‘benign ethnic
neutropenia’’, can have important effects on medical decision-
making, since WBC is a valuable indicator of immunocompetence,
infection, and inflammation. To seek the genetic basis of benign
ethnic neutropenia, we recently carried out an admixture mapping
analysis in which we identified a locus on chromosome 1 where
local inheritance of African or European ancestry is sufficient to
account entirely for the epidemiological differences in WBC levels
between African Americans and European Americans [6]. By
genotyping samples from two epidemiological cohorts—the
Health Aging and Body Composition Study (Health ABC) and
the Jackson Heart Study (JHS)—at a panel of markers that were
extremely differentiated in frequency between Africans and
Europeans, we identified an approximately 900 kilobase locus on
chromosome 1 (99% credible interval of 155.46–156.36 Mb)
where individuals with low WBC had increased African ancestry
compared with the average in the genome.
In the present study, we narrowed the region of association from
900 kb to a single base pair substitution that is likely to have a
strong effect on variation in WBC. To achieve this, we increased
our sample size from 1,550 in the initial study to 6,005, by pooling
samples from the Jackson Heart Study (JHS), the Health ABC
Study, and the Atherosclerosis Risk in Communities (ARIC)
Study. We found that neutrophil count is responsible for the vast
majority of the WBC association at the locus, and therefore
focused on neutrophil count in the current analysis. We also
showed that the genetic change that is probably responsible is the
Duffy Null polymorphism (rs2814778, also called FY+/2), which
is already known to protect individuals of African descent against
Plasmodium vivax malaria infection [7,8], and which has recently
been associated with susceptibility to HIV infection and rate of
progression to AIDS [9]. Our identification of this polymorphism
as the probable cause of benign ethnic neutropenia should prompt
further investigation of its effects on hematopoiesis and immunity.
Results
Merging Samples across the JHS, ARIC, and Health ABC
Studies
We pooled 6,005 African American samples from three cohort
studies: the Jackson Heart Study (JHS), the Atherosclerotic Risk in
Communities (ARIC) Study, and the Health, Aging and Body
Composition (Health ABC) Study. For each sample, we required a
high quality genome-wide admixture scan (Materials and
Methods), a genotype at SNP rs2814778, body mass index
(BMI), age, gender, and a full differential white blood cell count
(with the exception that for Health ABC samples we did not
require a measurement of bands).
To explore correlations between the genetics and the pheno-
type, we first used the genotype at SNP rs2814778, which occurs
at position 155,987,755 in Build 35 of the human genome
reference sequence, within the 99% credible interval defined by
our previous admixture mapping study [6]. This SNP is also
known as the ‘‘FY+/2’’ or ‘‘Duffy’’ variant, and the FY2 allele is
very highly correlated to West African ancestry. For example, it is
completely fixed in frequency in West African and European
American samples from the International Haplotype Map [10]
(although it is not completely fixed in larger sample sizes from
these populations; see below). For Figure 1 and Tables 1 and 2, we
used the genotype at rs2814778 as a surrogate for ancestry because
the genotype can be conveniently read out as a discrete value (0, 1
or 2 copies) rather than as a continuous value, and is
extraordinarily correlated to ancestry (r
2.0.99). Later, we
demonstrate that there is in fact a slightly stronger association to
neutrophil count for rs2814778 than for ancestry, which is
important in showing that the FY2 allele at this polymorphism
may actually be responsible for low neutrophil counts, and is not
just in admixture linkage disequilibrium with the causal allele.
To test for heterogeneity in the strength of the genetic
association to WBC among the different sample sets that
comprised our study, we divided the samples into four groups.
There were 658 samples from the Health Aging and Body
Composition Study (‘‘Health ABC’’), 1,969 samples from the JHS
cohort only (after randomly dropping samples until there was only
one from each pedigree; ‘‘JHS only’’), 2,476 samples from the
ARIC cohort only (‘‘ARIC only’’), and 902 samples that
overlapped between JHS and ARIC (‘‘JHS-ARIC overlap’’). For
the JHS-ARIC overlap samples, we averaged all phenotype
measurements, taken an average of 14 years apart at the time the
participant entered each study (and having a correlation coefficient
of r
2=0.37), to provide a more precise estimate of the phenotype
than would be available from either measurement alone.
Table 1 presents the characteristics of each of the groups of
samples. We found that all sets of samples showed quantitatively
similar associations to the chromosome 1 locus. In particular, for
neutrophil count, individuals carrying at least one European-type
(‘‘FY+’’) allele of rs2814778 had 1.58–1.65 times higher values,
depending on the study, than individuals homozygous for African
ancestry (FY2/2), a tight enough range that we decided to pool all
four groups of samples for subsequent analyses. Despite the similar
correlation of neutrophil count to local ancestry across studies, we
observed that the correlation coefficient to ‘‘European carrier
status’’ was significantly higher for JHS-ARIC overlap samples,
r=0.57, than for the samples for which only one measurement was
made: r=0.52 for JHS-only (P=0.03 for a reduction) and r=0.50
Author Summary
ManyAfricanAmericanshave whiteblood cell counts (WBC)
that are persistently below the normal range for people of
European descent, a condition called ‘‘benign ethnic
neutropenia.’’ Because most African Americans have both
African and European ancestors, selected genetic variants
can be analyzed to assign probable African or European
origin to each region of each such person’s chromosomes.
Previously, we found a region on chromosome 1 where
increased local African ancestry completely accounted for
differences in WBC between African and European Amer-
icans, suggesting the presence of an African-derived variant
causing low WBC. Here, we show that low neutrophil count
is predominantly responsible for low WBC; that a dominant,
European-derived allele contributes to high neutrophil
count; and that the frequency of this allele differs in
Africans and Europeans by .91%. Across the chromosome
1 locus, only the well-characterized ‘‘Duffy’’ polymorphism
was this differentiated. Neutrophil count was more strongly
associated to the Duffy variant than to ancestry, suggesting
thatthe variantitself causesbenign ethnic neutropenia. The
African,or‘‘null,’’formofthisvariantabolishesexpressionof
the ‘‘Duffy Antigen Receptor for Chemokines’’ on red blood
cells, perhaps altering the concentrations and distribution
of chemokines that regulate neutrophil production or
migration.
Duffy Variant and Neutropenia
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reflect a more accurate assessment of basal neutrophil count when it
was measured twice and averaged over different environmental
conditions (the baseline measurements in JHS and ARIC studies
taken an average of 14 years apart) than when it was measured only
once. In support of this hypothesis, the JHS-ARIC overlap samples
contributed more per sample to the statistical signal than those
measured in only one cohort: 28% more per sample on average,
which we calculated by dividing the LOD score they contributed by
the total number of samples.
Dominant Effect of European Ancestry on WBC Counts
Combining all samples (n=6,005 in total) and working with
normally transformed cell counts for each white blood cell lineage
(Materials and Methods) we explored how counts of total WBC
and each of the 6 differential counts were associated with ancestry
at the locus, using the genotype at rs2814778 as a surrogate for
ancestry (Table 2).
There was strong evidence that the allele at the locus that
contributed to high white blood cell count had an almost purely
dominant effect. As shown in Table 2, there was no significant
Figure 1. Relationship between ancestry and the distribution of neutrophil count. (A) Distribution of normally transformed absolute
neutrophil count for the three classes of genotype at rs2814778. Individuals who are homozygous for the null allele have distinctly lower neutrophil
count (20.3560.89 standard deviations compared with the mean) than individuals who are carriers for the functional allele (0.7660.89). We were
able to place constraints on the frequency of the high neutrophil count allele in (B) West Africans, and (C) European Americans by assuming that the
observed distributions of neutrophil count for each ancestry class (which we marked in practice by the genotype at rs2814778) are a mixture of
distributions specified by the underlying allele frequency. The results indicate a 99% probability that the frequency is ,4.9% in Africans and also a
99% probability that the frequency is .95.2% in Europeans.
doi:10.1371/journal.pgen.1000360.g001
Duffy Variant and Neutropenia
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with two copies of European ancestry at this locus (FY+/+) and
1,647 African Americans who were FY+/2 (P.0.08 for WBC and
all differential counts). By contrast, being FY+/+ or +/2 (1,894
African Americans) vs. FY2/2 (4,111 African Americans) was
strongly associated to counts of all white blood cell types except
bands (P,,10
24; Table 2).
The dominant effect of European ancestry on white blood cell
count is also visually apparent in Figure 1, which shows the
distribution of neutrophil count for individuals grouped according to
genotypeatrs2814778.Personscarryingatleastone FY+allelehada
distribution of neutrophil counts that was shifted by 1.3 standard
deviations above that of persons who were FY2/2 (this was
extraordinarily statistically significant: Z=49.7). By contrast, there
was no significant difference between individuals who carried either
one or two FY+ alleles (Z=0.6). For further analysis, we pooled
individuals who were carriers of the FY+ allele at this locus.
Low Neutrophil Count Is the Main Phenotype Underlying
the WBC Association
The differential white blood cell count that was most
significantly associated with ancestry was absolute neutrophil
count (calculated as total WBC multiplied by the percentage of
neutrophils). The correlation (r) of normally transformed absolute
neutrophil count to carrier status for the FY+ allele was 0.519,
which was higher than that of the general WBC phenotype
originally mapped to the locus [6] (r=0.458). In the 952 African
Americans who had absolute neutrophil counts at least 1 s.d.
below the mean (roughly ,1,800 /mm
3), the proportion of FY+
allele carriers was reduced by more than an order of magnitude
compared with the genome wide average.
Neutrophil count was responsible for the vast majority of WBC
association at the locus. After controlling for neutrophil count in a
regression analysis, only monocyte count (r=0.025, P=0.05) and
basophil count (r=20.034, P=0.009) remained nominally
associated, and these associations were not significant after
correcting for the 6 hypotheses tested (Table 2). The weak
evidence of association to monocyte and basophil counts may reflect
a real effect, or may be a false-positive due to multiple hypothesis
testing. It is also possible that the result may be an experimental
artifact related to the Coulter Counter technology used to measure
differentialWBC.Inthesemeasurements,thepositionsofmonocytes
and basophils were near those of neutrophils in the plots used for cell
classification. Even a small amount of misclassification among
neutrophils, monocytes, and basophils (a couple of percent) could
cause their counts to be artifactually correlated, contributing to the
signals we observe in the context of measurements in large sample
sizes. Since neutrophil count appears to drive at least the great
majority of association, we focused on this WBC phenotype for all
further analysis
Epidemiological Impact of the Chromosome 1 Locus on
Neutrophil Count
To assess whether the higher neutrophil count observed in
European Americans compared with African Americans can be
entirely accounted for by ancestry at the chromosome 1 locus, as is
the case with total WBC [6], we examined samples from the
Health ABC study (1,331 European Americans and 658 African
Americans). Among African Americans who could be classified
with confidence as carrying at least one chromosome of European
ancestry at the locus, the absolute neutrophil count did not differ
from that of European Americans (P=0.99). Thus, genetic
variation at the chromosome 1 locus was sufficient to account
for the entire epidemiological difference across these populations.
The predictive effect of ancestry at the chromosome 1 locus was
profound. Carrier status for the European-type (FY+) allele at the
rs2814778 variant predicted 26.95% of the variance in normally
transformed neutrophil count, which was far more than the 3.37%
Table 1. Comparison of phenotypic characteristics for the four sets of samples used in this study.
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JHS only 1,969 1,349 52 (21–84) 32 (15–66) 60% 18.1% 5.58 3.09 .004 1.93 .387 .138 .030 1.58 29.0 .519 (.016)
ARIC only 2,476 1,749 54 (44–66) 30 (14–66) 60% 17.7% 5.73 2.85 .158 2.13 .347 .167 .035 1.65 30.4 .497 (.014)
*JHS-ARIC
overlap
902 617 59 (50–74) 31 (18–59) 67% 17.8% 5.46 2.87 .080 1.94 .359 .145 .034 1.64 21.5 .568 (.021)
Health ABC 658 396 73 (69–80) 29 (16–43) 62% 21.3% 5.59 2.96 Not
avail
1.93 .473 .172 .059 1.62 16.6 .532 (.026)
Pooled 6,005 3,958 56 (21–84) 30 (14–66) 61% 18.2% 5.63 2.94 .088 2.02 .376 .155 .036 1.62 49.7 .519 (.009)
Note: For the differential white blood cell counts, we present absolute values, obtained by multiplying the differential counts (expressed as a percentage of total WBC)
by the total WBC. The Health ABC study did not obtain band counts.
*For the JHS-ARIC overlap samples, the values of all phenotypes (age, BMI, and differential white blood cell counts) are averaged between the JHS and ARIC baseline
measurements, taken an average of 14 years apart. Analyses in all other groups use a single measurement at the cohort baseline.
1Average percentage of European ancestry was estimated using the ANCESTRYMAP software. European ancestry ‘‘carrier status’’ was defined by rs2814778 genotype.
{Neutrophil count is used to assess the genetic association, since it accounts for essentially all the correlation to the chromosome 1 locus and thus provides the best
measure of association (text and Table 2). Association analyses are carried out on the normally transformed rank-ordered values of the absolute neutrophil count.
Standard errors on the correlation coefficients are obtained by a leave-1-out jackknife analysis.
doi:10.1371/journal.pgen.1000360.t001
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controlling for rs2814778 genotype, there was no longer any
association to genome-wide European ancestry. Similarly, after
controlling for rs2814778 genotype, BMI and gender only
predicted 0.79% and 0.14% of variance in neutrophil count
respectively, while smoking (analyzed in JHS only) only predicted
0.8% of the variance. Age was not significantly associated to
neutrophil count in our data (P=0.25). We did not analyze other
phenotypes like hypertension and coronary artery disease status
for their correlation to neutrophil count. Because of the relatively
weak contributions of all the non-genetic predictors we analyzed,
we focused subsequent analyses on genotype at the chromosome 1
locus uncorrected for covariates.
The Causal Allele must be .91% Differentiated between
Africans and Europeans
We were able to place strong constraints on the frequency of the
variant affecting neutrophil count by analyzing the distributions of
neutrophil count for individuals with 0, 1 and 2 copies of
European ancestry at the chromosome 1 locus, which in practice
we marked by the genotype at rs2814778. The analysis in
Figure 1A provides strong evidence of a dominant allele of
European origin contributing to high neutrophil count. We
modeled the frequency of the variant that causes high neutrophil
count by defining 6 parameters. The frequency of this variant in
Africans was specified as PA and its frequency in Europeans as PE.
Individuals who were homozygous for the other allele were
assumed to have a normal distribution of neutrophil count with
mean mL and standard deviation sL, and carriers of the ‘‘high
neutrophil’’ allele were assumed to have a normal distribution of
neutrophil count with mean mH and standard deviation sH.
Studying a grid of values of PA (Figure 1B), and another grid of
values of PE (Figure 1C), we found the combination of the
remaining variables that provided the best fit to the data, as
assessed by a chi-square goodness-of-fit statistic. Given each set of
6 model parameters, we calculated a likelihood of the data for all
6,005 individuals. This resulted in a marginal likelihood surface for
PA (Figure 1B) and PE (Figure 1C), which we used to place
constraints on these parameters.
Fitting this 6-parameter model to the data, we inferred that the
frequency of the allele contributing to high neutrophil counts was
,4.9% in Africans and .95.2% in Europeans (Figure 1B, C), and
that the difference in frequency between populations was .91.9%.
Compared to 3.54 million autosomal SNPs in the November 2006
Phase2 HapMap data set [10], there were only 115 SNPs with a
frequency differentiation at least this extreme, and only one in the
region of admixture association: the SNP rs2814778 (at position
155.99 Mb), the same SNP we used as a marker of ancestry. This
variant already has a known phenotype—susceptibility to
Plasmodium vivax malaria—but it had not been hypothesized to
be associated with low white blood cell count until it was found to
lie within this locus [6]. While rs2814778 is a plausible candidate,
the locus we described previously [6] spans 900 kb, and there
could in principle be other variants within this span—unreported
in the literature or in genome variation databases—that have a
high enough frequency differentiation to explain the signal. In
what follows, we present additional lines of evidence to rule out the
great majority of sites other than rs2814778 as consistent with
explaining the signal.
Combining Information across Cohort Studies Halves the
Admixture Peak to 450 kb
We used four strategies to increase the height of our admixture
association peak and thereby to narrow the position of the allele
affecting neutrophil count. First, we used the fact that with 6,005
samples in our admixture mapping analysis pooled across three
Table 2. Effect of the chromosome 1 locus on white blood cell counts.
Raw values of differential white blood cell counts
Rank-order transformation of differential
WBC counts
Correlation (r) of WBC rank-
order to ancestry
Z-scores for association tests
African
ancestry
homo-
zygotes
(n=4,111)
(std. err.)
Afr/Eur
ancestry
hetero-
zygotes
(n=1,647)
(std. err.)
European
ancestry
homo-
zygotes
(n=247)
(std. err.)
Ratio of
1,894 Eur
ancestry
carriers to
4,111 Afr
ancestry
homozygotes
Afr anc.
homozy-
gotes
vs. Afr/Eur
hetero-
zygotes
Afr anc.
homozy-
gotes vs.
Eur anc.
homo-
zygotes
Afr/Eur
anc heter-
ozygotes
vs. Eur
anc.
Homo-
zygotes*
Afr anc.
Homo-
zygotes
vs. Eur
ancestry
carrier*
r between
European
ancestry
carrier and
phenotype*
r between
Eur ancestry
carrier and
phenotype
correcting
for neut.
level {
Total WBC 5.085 (.024) 6.798 (.045) 6.847 (.109) 1.34 39.4 19.4 0.7 41.6 .458 Not significant
Neutrophils 2.459 (.017) 3.982 (.034) 4.013 (.084) 1.62 47.2 23.2 0.6 49.7 .519 Not applicable
Bands 0.080 (.004) 0.107 (.008) 0.100 (.017) 1.32 0.6 0.1 20.1 0.6 Not
significant
Not significant
Lymphocytes 1.995 (.012) 2.06 (.018) 2.081 (.048) 1.03 3.9 2.0 0.3 4.2 .054 Not significant
Monocytes 0.351 (.003) 0.427 (.004) 0.438 (.012) 1.22 16.9 7.6 0.5 17.8 .222 .025 (P=.05)
Eosinophils 0.149 (.002) 0.169 (.004) 0.157 (.007) 1.13 6.1 2.0 20.9 6.2 .080 Not significant
Basophils 0.034 (.001) 0.041 (.001) 0.038 (.002) 1.17 6.7 1.1 21.7 6.5 .085 2.034 (P=.009)
*European ancestry at the locus has an essentially dominant effect on white blood cell counts. None of the differential counts phenotypes shows a significant difference
between the 1,647 FY2/FY+ heterozygotes and 247 FY+/FY+ homozygotes after correcting for 7 hypotheses tested (Bonferroni corrected P=0.48). However, all white
blood cell counts except bands show significant associations comparing the 4,111 FY2/FY2 homozygotes to the 1,894 carriers of the FY+ allele (Z-scores between 4.2
and 49.7 standard deviations).
{After controlling for neutrophil level, there is weak additional evidence for association to the chromosome 1 locus only for monocytes and basophils. For subsequent
mapping analyses we only focused on neutrophil levels, as adding these other residuals did not substantially increase the strength of the association. We do not
estimate correlation coefficients of the associations that are not significant.
doi:10.1371/journal.pgen.1000360.t002
Duffy Variant and Neutropenia
PLoS Genetics | www.plosgenetics.org 5 January 2009 | Volume 5 | Issue 1 | e1000360studies (Table 3), we had a greater sample size than the 1,550
samples that were used initially [6]. Second, we designed an
analysis (Materials and Methods) that used all of the samples
instead of just the extremes of the distribution [6]. Third, we
changed the phenotype from total WBC (r=0.458 correlated to
ancestry at the locus) to absolute neutrophil count (r=0.519) to
obtain a sharper statistical signal. Finally, we genotyped the JHS
samples (including the JHS-ARIC overlap samples) at additional
ancestry informative markers, spaced at a density of about 1 every
400 kb across the peak, to increase spatial resolution.
Using all 6,005 samples and the stronger phenotype of absolute
neutrophil count, the LOD score (log base 10 of the Bayes score)
rose to 363.1 (Table 3; Figure 2). The 99% credible interval was
narrowed to ,450 kb (155.957–156.407 kb), and still contained
the Duffy null polymorphism at position 155,987,756 near the
DARC gene (Entrez GeneID: 2532), as well as a handful of other
genes listed in the lower panel of Figure 2.
rs2814778 Is Significantly More Predictive of Neutrophil
Count than Is Ancestry
We exploited the large sample size (6,005 individuals) to test
whether the rs2814778 variant predicted low neutrophil count
more than would be expected from the association to ancestry [6].
This is a difficult problem since the genotype at this SNP is highly
correlated to ancestry. By using the ANCESTRYMAP software
and the data from all 6,005 African Americans, we estimated that
the frequency of FY+ allele at rs2814778 is 0.260.1% in Africans
and 99.360.4% in Europeans (this frequency distribution is
consistent with the allele frequencies inferred for the causal allele
based on modeling of neutrophil counts in Figures 1B and 1C).
Thus, if rs2814778 is the causal variant, there should be a small
handful of individuals for whom the genotype at rs2814778 is
discrepant with ancestry, who will be informative for our analyses.
To estimate the number of individuals who we expect to be
informative for testing association of rs2814778 above and beyond
ancestry, we used the fact that the cohort has 18.2% European
ancestry on average (Table 2). Thus, we expected there to be about
Table 3. Stratification of samples into 12 groups for
admixture mapping analysis.
Standard deviations
compared with
population mean Samples
Risk model used
(factor change in
European ancestry
vs. genome average)
LOD score at
rs2814778
,21.5 400 0.04 46.6
21.5 to 21.0 552 0.05 64.8
21.0 to 2.75 408 0.11 35.2
2.75 to 2.5 493 0.19 28.6
2.5 to 2.25 557 0.3 22.9
2.25 to 0 593 0.56 7.1
0 to .25 593 0.98 0.1
.25 to .5 558 1.6 4.6
.5 to .75 492 2.5 17.5
.75 to 1 408 3.5 27.8
1 to 1.5 552 5 53.8
.1.5 399 6.5 54.0
Sum across all 6,005 363.1
doi:10.1371/journal.pgen.1000360.t003
Figure 2. Admixture association defines a 451 kb region containing the risk allele. The LOD score for admixture association to neutrophil
count shows a peak of 363.1, and a 99% confidence interval of 155.957–156.408 Mb (the region where the LOD score is within 1.44 of its maximum). The
known genes under the peak are obtained using a screenshot of the ‘‘Known Genes’’ track from the UCSC genome browser (http://genome.ucsc.edu).
doi:10.1371/journal.pgen.1000360.g002
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rs2814778 but heterozygous for European ancestry: 13=(6005)6
(2618.2%681.8%)6(0.7%). Similarly, we expected there to be
about 8 individuals who are heterozygous at rs2814778 but
homozygous for local African ancestry: 8=(6005)6(81.8%6
81.8%)6(0.2%).
To test for association to rs2814778 above and beyond ancestry,
we first obtained estimates of European ancestry at the position of
the SNP using the ANCESTRYMAP software [11]. We included
rs2814778 in the ancestry estimation so that we could explicitly
test whether the genotype at this SNP alone was more predictive of
neutrophil count than this SNP plus flanking markers. This would
be evidence that it was more associated than African ancestry
itself. Our power to detect a signal was highest for JHS samples,
which were genotyped at a high density at the chromosome 1
locus. Consistent with this observation, the 7 samples for which we
could state with .50% confidence that the local ancestry was
discrepant with the expectation from the rs2814778 genotype were
all from JHS.
We performed three regression analyses (Table 4) to explore
whether rs2814778 or ancestry status at the chromosome 1 locus
was a better predictor of neutrophil count. (a) First, we obtained a
x
2 statistic for association of carrier status for the rs2814778 FY+
allele to neutrophil count; (b) second, we obtained a x
2 statistic for
association of carrier status for European ancestry to neutrophil
count (using the rs2814778 genotype in the estimate); and (c) third,
we obtained a x
2 statistic for association of both predictors
together. We found that there was a significant difference between
the strength of association of ancestry alone and ancestry and
genotype together: (c)-(b)=15.7 (P=3.8610
25). Testing for the
reverse effect of ancestry above and beyond the genotype of
rs2814778 produced no signal: (c)-(a)=0.4 (P=0.74). These results
confirm that rs2814778 is predictive of neutrophil count, above
and beyond the effect of ancestry.
A Fine-Mapping Scan Fails to Find Additional Signals of
Association
To search for additional alleles in the admixture peak that might
be associated to neutrophil count beyond the main effect, we
genotyped a dense panel of 193 SNPs across the region in 148
individuals with low neutrophil count (,20.7 standard deviations
below the mean) and 74 individuals with high neutrophil count
(1.3–2.8 standard deviations above the mean). We chose only
individuals for whom we were .99% confident of all African
ancestry at the locus, based on genotyping information at flanking
markers excluding rs2814778, so that ancestry would not be a
confounder of the analysis.
We genotyped these individuals for a set of SNPs chosen using
Tagger [12] to capture the great majority of common variation
across the admixture peak in both West Africans and Europeans
(Materials and Methods). After the genotyping was complete, we
had captured 94% of SNPs of .5% minor allele frequency in
West Africans, and 96% of SNPs of .5% minor allele frequency
in European Americans, both at a correlation of r
2.0.8
(Figure 3B).
Case-control association analysis of these 193 SNPs identified
only one, rs2814778, that was significantly associated (nominal
P=2.1610
25; Figure 3A) after a Bonferroni correction for 193
multiple hypothesis tests. Thus, there was no evidence of any allele
in the region that is associated to neutrophil count beyond the
effect that is already captured by rs2814778.
Genotyping of rs2814778 in .10,000 European
Americans with a Neutrophil Count
We genotyped 10,062 self-identified European Americans in the
ARIC study for rs2814778, searching for a decreased neutrophil
count in association with the null allele. This analysis should have
little power if the European American population is in Hardy-
Weinberg equilibrium, since FY2/2 homozygotes are expected to
occur very rarely among Europeans: less than 1/10,000 based on
the observed frequency of the null allele in this population
(0.34=10,06260.58%60.58%). Interestingly, we observed 7
European Americans with FY2/2 genotypes, a significant excess
compared with expectation (P,4610
29) suggesting that European
Americans harbor population substructure with variable levels of
African ancestry. Among the FY2/2 homozygotes we found a
non-significant reduction in WBC associated with the null allele:
WBC was observed to be 5.962.6 for the 7 FY2/2 homozygotes,
5.961.8 for the 103 FY+/2 heterozygotes, and 6.361.9 for the
9,952 FY+/+ homozygotes (P=0.06 with an additive model and
P=0.35 with a dominant model using 1-sided tests). Genotyping
of rs2814778 in 1,339 self-identified European Americans from
the Health ABC study identified 26 heterozygous individuals, and
none homozygous for FY2/2.
Exclusion of Most Single Nucleotide Changes in the
Admixture Peak Other than rs2814778
These analyses strongly increase the likelihood that a single
nucleotide change at the site of the rs2814778 polymorphism is
responsible for low neutrophil counts, and provide no evidence of
any other allele contributing a signal. However, these findings do
not rule out the existence of undiscovered variants in the
admixture peak that are differentiated enough to explain the
signal. If such variants existed, then rs2814778 could simply be a
Table 4. Reduced neutrophil count is more associated to the Duffy null polymorphism than to ancestry.
x
2 value for association of neutrophil count to a predictor
(n=5,997 individuals passing analysis quality filters)
Carrier status for SNP allele (x
2 from 1-variable regression) 1883.2
Carrier status for European ancestry* (x
2 from 1-variable regression) 1867.9
SNP and ancestry* together (x
2 from 2-variable regression) 1883.6
Association to SNP beyond ancestry (x
2 subtracting lines 3–2, one-sided test) 15.7 (P=3.8610
25)
Association to ancestry beyond SNP (x
2 subtracting lines 3–1, one-sided test) 0.4 (P=0.74)
*For the association tests, we used ancestry estimates that included the genotype of the SNP. This ensures that any association at the SNP is above and beyond that
expected from ancestry alone.
doi:10.1371/journal.pgen.1000360.t004
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than being causal itself.
We carried out an analysis in which we systematically ruled out
the majority of other nucleotides in the region as potentially
contributing to the signal. We examined genomic databases to
identify DNA sequence fragments that are known to be of either
African or European ancestry and that overlap the admixture
peak, and considered nucleotides where all African chromosomes
had one allele and all European chromosomes had the other.
Based on our modeling in Figure 1, it is likely that the causative
variant is sufficiently differentiated that it would be found by this
discovery strategy.
We mined shotgun sequencing data from 6 individuals of West
African ancestry and 5 individuals of European ancestry (Materials
and Methods). We restricted analysis to nucleotides for which we
had a high sequence quality score (Neighborhood Quality Score of
$40) [13], randomly sampling one sequence to represent each
individual. We supplemented the shotgun data with the human
genome reference sequence, which is comprised of a mosaic of
sequence from 5 BAC clones across the region. We determined
that 3 of the clones (one from individual CIT978SK and two from
individual RPCI-11) were of European ancestry, and 2 were of
African ancestry (both from RPCI-11) (Figure 4). Interestingly,
since RPCI-11 was heterozygous for African and European
ancestry at this locus, this individual is probably African American.
Because RPCI-11 is the source for most (,74%) of the human
genome reference sequence [14], we conclude that much of the
public human genome reference sequence is that of an African
American, and includes a substantial amount of sequence of
African ancestral origin.
Figure 3. Fine mapping reveals rs2814778 as the only significant association. (A) Results of case-control association analysis for 193 SNPs
genotyped in 148 individuals with low neutrophil count (,2,100/mm
3), which we compared with 74 controls with high neutrophil count (5,000–
9,000/mm
3). All samples were selected to have a confident estimate of all African ancestry at the chromosome 1 locus (.99% probability) based on
ANCESTRYMAP analysis at flanking markers outside the admixture peak. (B) HapMap SNPs of .5% minor allele frequency are well captured by this
genotyping. We find that 94% of West African SNPs and 96% of European American SNPs are correlated with r
2.0.8 to one of the SNPs we
genotyped.
doi:10.1371/journal.pgen.1000360.g003
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least one chromosome from each population (an average of 2.26
European and 2.16 African coverage). Of the 817 SNPs we
identified, 594 could be ruled out as not completely differentiated
in frequency between the European and African chromosomes
used in SNP discovery, an additional 79 could be ruled out as not
sufficiently differentiated across populations based on data from
the International Haplotype Map database [10], and 49 could be
ruled out by their allele frequencies in our own follow-up
genotyping of HapMap samples. Thus, 88.5% (=(594+79+49)/
817) of SNPs discovered in the admixture peak could be ruled out.
This allowed us to infer that 72.8% (=82.3%688.5%) of
nucleotides can be excluded as causal for the observed major
effect on variation in neutrophil count.
These results provide yet another line of evidence that the
rs2814778 single nucleotide change may itself be causing low
neutrophil levels. There are now five reasons why we believe
rs2814778 is likely to be the direct cause for low neutrophil count:
(1) rs2814478 falls within the ,450 kilobase admixture peak. (2)
rs2814778 contributes a signal of association above and beyond
the admixture signal, showing that the true underlying causal
variant is in an even narrower region around rs2814478. (3)
rs2814778 is already known to have functional consequences,
based for example on past molecular work showing that it affects
expression of an antigen on red blood cells and thus modulates
resistance to P. vivax malaria. (4) rs2814778 is known to have a
frequency differentiation across populations that makes it
consistent with the underlying causal variant; a degree of
differentiation that is extremely unusual, with only 0.003% of
known SNPs in the genome having a differentiation this extreme.
(5) Genome sequencing data directly rule out about three quarters
of other nucleotides in the admixture peak as containing the
variant. (We have not carried out a similar analysis of insertion/
deletion polymorphisms, which are known to occur at about a
tenth the rate of SNPs.)
We caution that an association study is always correlational, and
can never by itself prove a functional effect of an allele. To prove
causality, it is essential to follow up any association study with
biological work. Nevertheless, the present study provides the best
example of which we are aware of taking association analysis to its
limit, and using association analysis to demonstrate a likely causal
effect. Our study justifies further work to understand the biological
mechanism by which a single nucleotide change at rs2814778
probably causes reduced neutrophil counts.
Discussion
We have used admixture mapping to localize a variant affecting
neutrophil levels to a region of about 450 kb centered on the Duffy
null locus. We have further shown that the underlying variant
must be .91% different in frequency between West Africans and
European Americans, placing it among the top 115 HapMap
SNPs in the genome in terms of allele frequency differentiation
(top 0.003%). Since only one SNP in the admixture peak, the
Duffy null polymorphism rs2814778, is known to be this
differentiated in frequency across populations, we tested this
SNP for evidence of association above and beyond the ancestry
effect, and found a signal (P=3.8610
25). Finally, we ruled out the
great majority of nucleotides across the region, apart from
rs2814778, as sufficient to cause the signal.
Methodologically, these results provide a case-example of fine-
mapping in a difficult context. We have moved from an initial
association signal discovered via mapping by admixture linkage
disequilibrium, to a more fine-grained association based on linkage
disequilibrium inherited from the ancestral African and European
populations, and finally to an analysis where we systematically
excluded the great majority of nucleotides in the region as
contributing to the association.
The study is also novel in demonstrating the value of mapping
in multi-ethnic and admixed populations. The variant could not
Figure 4. Ancestry analysis of BAC clones that are the source of the human genome reference sequence across the chromosome 1
locus. The human genome reference sequence across the admixture peak is pieced together from 5 BAC clones, which turn out to be a mosaic of
European and African ancestry. To determine ancestry, we examined the haplotype of the human genome reference sequence for 284 SNPs for which
data are available from the International Haplotype Map Project, and then output the ratio of the number of perfect matches to the reference
sequence haplotype in 120 European American to the number of perfect matches in 120 West African chromosomes (conservatively adding 1 to the
counts). Values above 10 indicate strong (.10:1) evidence for a European haplotype, and values below 0.1 indicate strong (,1:10) evidence for an
African haplotype. RPCI-11, the individual who is the source of ,74% of the human genome reference sequence, has two clones of entirely African
and two clones of entirely European ancestry at this locus, strongly indicating that the human genome reference sequence is primarily that of an
African American. We included these BAC clones in our search for polymorphisms across the admixture peak that were consistent with being fixed in
frequency between European and African populations.
doi:10.1371/journal.pgen.1000360.g004
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Europeans), since it is nearly fixed in both populations, showing
how studying diverse populations is important in biology. For
example, when we genotyped rs2814778 in more than 10,000
European Americans from the ARIC study, we could not obtain a
replication despite the large sample size.
The mechanism of low neutrophil count in persons homozygous
for the FY2 allele is unknown. Interestingly, Yemenite Jews also
have a high frequency of the FY2 allele [15], which we hypothesize
explains the occurrence of reduced neutrophil count in this group.
The term ‘‘ethnic neutropenia’’ has been applied to persistently low
neutrophil count in both Yemenite Jews and in populations of
African ancestry, and the condition is clinically similar in these two
populations. Persons with ethnic neutropenia have a reduced
capacity to mobilize bone marrow neutrophil reserves in response
to corticosteroids, despite normal cellularity and maturation of all
cell lines in bone marrow aspirates [16–18]. Exercise-induced
increments in neutrophil counts (demargination) are also smaller in
persons with ‘‘ethnic neutropenia’’ than in healthy volunteers. Thus,
the low neutrophil count is not the result of increased sequestration
of neutrophils in the marginated granulocyte pools (cells adherent to
the endothelium of post-capillary venules) [19].
The FY2 allele of rs2814778 has a 246 T to C substitution
(non-coding strand) in the Duffy Antigen Receptor for Chemo-
kines (DARC) gene, which disrupts a binding site for the GATA1
erythroid transcription factor [20]. This substitution abolishes
gene expression in erythrocytes but not other cell types, such as
endothelial cells of the post-capillary venules [21]. The DARC gene
product is a seven-transmembrane receptor that selectively binds
‘‘inflammatory’’ chemokines of both the CXC and CC families,
including, for example, CXCL8 (interleukin 8) and CCL5
(RANTES), both of which are involved in neutrophil recruitment
[22–25]. Unlike related chemokine receptors with signaling
function, DARC lacks a G-protein binding motif. It is nevertheless
capable of internalizing bound chemokine [21], and it has been
hypothesized to affect leukocyte recruitment to sites of inflamma-
tion through its role in trancytosis of chemokines through
endothelial cells [24–26]. DARC on red blood cells might affect
the number of circulating neutrophils through any of several
mechanisms, for example, by modulating the concentrations of
chemokines in vascular beds in the bone marrow [25], or by acting
as a chemokine ‘‘sink’’ to limit the stimulation and extravasation of
circulating neutrophils, or through other mechanisms that are not
yet understood. Interestingly, DARC-knockout mice, which lack
DARC expression not only on red blood cells but also in other
tissues, do not differ from wild-type mice in peripheral blood
leukocyte levels [27], but have a different phenotype, of increased
bone mineral density [28]. When we tested whether an association
with bone mineral density existed in African Americans in the
Health ABC cohort, however, rs2814778 genotype was not
significantly associated with either total (n=1,141, P=0.57) or
femoral neck (n=1,141, P=0.43) bone mineral density.
The expression of DARC on erythrocytes is known to modulate
chemokine levels after endotoxin treatment [29]; thus the FY2 allele
could potentially have important effects in critically ill patients with
sepsis. More subtle effects on innate immunity and inflammation
could also exist through DARC modulation of chemokine
concentrations in specific vascular and tissue microenviroments[25].
However, we were not able to directly demonstrate an effect of the
FY2 allele on health. When we carried out tests of association of
FY2 to a wide range of phenotypes in the Health ABC Study (M.
Nalls and T. Harris unpublished data), we did not find association to
any phenotype. It is not surprising that health impacts of this variant
are subtle, since the allele has risen to nearly 100% frequency in
some African populations without being retarded in its rise by
natural selection. This forms a sharp contrast with the HBB allele,
which confers resistance to Plasmodium falciparum in heterozygous
individuals (analogous to FY2 conferring resistance to Plasmodium
vivax) but causes sickle cell disease in homozygous form, and as a
result has never risen to more than about twenty percent frequency
in any population.
Another recent study found that the FY2 variant of DARC is
associated to altered rates of HIV infection and disease
progression, potentially suggesting a health effect of the low
neutrophil count [9]. The authors found that there is a
significantly slower rate of disease progression in FY2/2
individuals infected by HIV-1 than in carriers of the FY+ allele.
To explore this result, they performed functional studies showing
that in vitro, HIV-1 attaches to erythrocytes via DARC and uses it
as a means of transfer to target cells. They argued that such
transfer might be impaired in FY2/2 individuals, leading to
slower disease progression. However, these authors also identified
a second phenotype that is associated to the FY2/2 genotype—a
40% higher rate of acquiring HIV-1 infection—that is difficult to
attribute to the same mechanism, since the failure to express
DARC on red blood cells might be expected to decrease access by
HIV-1 to CD4-positive target cells. Potential explanations are that
either low neutrophil counts or altered chemokine concentrations
due the FY2/2 genotype may have some role in modulating
infection. These possibilities should be testable in the laboratory. It
is also possible that differing frequencies of the FY2 allele reflect
stratification within the study population, and that differences in
DARC expression are not actually involved in modulating
susceptibility to infection or disease progression.
An immediate consequence of our finding is that genotyping of
rs2814778 (or measuring Duffy antigen expression on red blood
cells) might be used as a diagnostic guide in clinical situations in
African Americans, helping to set a baseline expected neutrophil
count for patients, and to guide treatment. Reduced neutrophil
count has been cited as a potential cause of treatment delay and of
less intensive therapy for early-stage breast cancer in African
American women, perhaps contributing to ethnic disparities in
breast cancer survival [30]. It also may alter the course of cytotoxic
therapy for inflammatory diseases such as rheumatoid arthritis and
systemic lupus erythematosus, perhaps needlessly. Finally, ‘‘ethnic
neutropenia’’ may contribute to a diminished leukocytic response
to infection [31–34], perhaps resulting in a lowered index of
suspicion and delayed diagnosis of infection in selected patients.
New studies are needed in each of these clinical settings to
incorporate genotyping information from rs2814778 to help in the
interpretation of neutrophil counts.
Materials and Methods
Human Subjects
The 6,005 human subjects for this study were drawn from three
observational cohorts in which large numbers of phenotypic
measurements had been made: the Jackson Heart Study (JHS)
[35], the Health, Aging and Body Composition (Health ABC)
Study [36], and the Atherosclerosis Risk in Communities (ARIC)
Study [37]. From each of these studies, we only included African
Americans for whom a complete differential white blood cell count
was available, including measurement of neutrophils, bands,
lymphocytes, monocytes, eosinophils and basophils. An exception
was the Health ABC study, which did not provide a measurement
of bands. In addition, we restricted our analysis to individuals for
whom we had an admixture scan that passed all our quality
control filters; for whom we had a genotype at the Duffy
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gender, age, and body mass index (BMI). All WBC and
phenotypic measures were from baseline data collected at the
time of enrollment in each study.
The JHS cohort [35] consists of 5,302 self-identified African
American men and women recruited between September 2000
and March 2004 from the three counties surrounding Jackson,
MS. Unrelated persons aged 35–84 were enrolled from three
sources: previous ARIC participants (31% of the total), random
selectees from a commercial listing (17%), and members of an age-
and sex-constrained volunteer sample (30%). The remaining
participants, at least 21 years old, were members of a nested family
cohort. A total of 3,945 JHS participants had the required
phenotypic data and were successfully genotyped for a panel of
admixture mapping markers. A subset of 2,871 was included in
our analysis after randomly dropping samples of related
individuals until there was only one individual included per
family. Of these, 1,969 were ‘‘JHS unique’’ samples that were
present only in JHS, and 902 were ‘‘JHS-ARIC overlap’’ samples,
representing persons who had participated in both the JHS and
ARIC studies. For the ‘‘JHS-ARIC overlap’’ samples, we averaged
the baseline measurements for each individual at the time of their
entry into each cohort, an average of 14 years apart.
The Health ABC cohort [36] consists of 3,075 men and women
aged 70–79 who were enrolled between April 1997 and June 1998.
All were Medicare beneficiaries living near Pittsburgh or Memphis
and all reported having no difficulty performing basic physical
activities. Of the 1,281 participants who identified themselves as
African American, 658 had complete genotype and phenotype
data and were included in the current study. Of the participants
who identified themselves as European American, 1,331 were
analyzed for the purpose of comparison with African Americans.
The ARIC cohort [37] consists of 15,792 randomly-selected
participants aged 45–64 who were recruited between November
1986 and December 1989, in roughly equal numbers, from field
centers in Jackson, MS, Minneapolis, MN, Forsyth County, NC,
and Washington County, MD. The cohorts of the latter three field
centers represent the ethnic mix of their communities. The
Jackson-based cohort (n=3,728) was limited to self-identified
African Americans, and comprised 87.4% of all African
Americans in ARIC (1,626 Jackson-based participants were later
enrolled in JHS). A total of 3,378 African American participants
were included in the present analysis after applying all data filters.
Of these, there were 2,476 ‘‘ARIC unique’’ participants who were
present only in ARIC. There were 902 ‘‘JHS-ARIC overlap’’
samples as described above. A total of 10,062 European American
ARIC participants were also genotyped and analyzed with respect
to a single variant, rs2814778.
Differential WBC
For all three studies, cells in EDTA-anticoagulated venous blood
were counted using a Beckman-Coulter Counter (Beckman Coulter,
I n c . ,F u l l e r t o n ,C A ) ,w h i c hc o m b i n e sm e a s u r e so fe l e c t r i c a lc o n -
ductivity and light scatter to distinguish cell lineages in suspensions of
unstained leukocytes, yielding an overall WBC and relative pro-
portions for each of six leukocyte subgroups: neutrophils, monocytes,
lymphocytes, basophils, eosinophils ,a n d‘ ‘ b a n df o r m s ’ ’ ,e x p r e s s e da s
a percentage of total WBC. Absolute counts were obtained by
multiplying the differential count (a percentage) by total WBC.
To create a phenotype for analysis, all counts were rank-ordered
within one of the four groups of samples (Health ABC, JHS only,
ARIC only and JHS-ARIC overlap), and then assigned a
percentile. An inverse normal transformation was used to translate
this percentile into a normally distributed phenotype.
Genotyping
Genotyping of African American samples on the admixture
mapping panels was performed using the Illumina BeadLab
platform [38], which can analyze a custom panel of 1,536 SNPs.
We have developed three consecutive versions of a custom
admixture mapping panel, each providing incrementally better
coverage of the genome than the previous version, and all yielding
excellent coverage. A total of 1,119 samples were genotyped in the
‘‘Phase 2’’ panel [39] (Health ABC samples and 16% of JHS
samples) and 4,886 samples were genotyped in the ‘‘Phase 3’’ panel
[6] (ARIC samples and 84% of the JHS samples). All panels include
the rs2814778 polymorphism in the DARC gene. The genotyping of
the Health ABC and JHS samples was carried out at the Broad
Institute of Harvard and MIT in Cambridge as previously described
[6]. Genotyping of the ARIC samples was carried out at the Center
for Inherited Disease Research (CIDR) in Baltimore, MD.
Genotyping of the rs2814778 polymorphism in 10,062 ARIC
European American samples and 1,339 Health ABC European
American samples was done using the ABI TaqMan technology [40].
Data Quality Checks for Ancestry Informative Markers
We used built-in data quality checks in the ANCESTRYMAP
software [11,39,41,42] to remove SNPs that were not appropri-
ately intermediate in frequency in African Americans compared to
the West African or European American ancestral populations, or
that had evidence of being in linkage disequilibrium (LD) with
each other in these ancestral populations [11]. After this filtering,
the JHS samples had 1,265–1,532 SNPs available for analysis, the
Health ABC study samples had 1,128–1,385 SNPs, and the ARIC
study samples had 1,277–1,529 SNPs.
Genotyping in JHS to Improve Spatial Resolution of the
Chromosome 1 Peak
To refine the peak of admixture association, we used the
Sequenom iPLEX platform [43] to genotype all JHS samples more
densely in the region of highest interest on chromosome 1 (153.5–
157 Mb in Build 35 of the reference sequence). After filtering to
remove SNPs in LD in the ancestral populations or with poor
genotyping performance, we had data from 9 markers across this
region in JHS (rs2768744, rs2309879, rs7528684, rs1587043,
rs857859, rs2814778, rs11265198, rs2494493 and rs11265352),
compared with 2 in the other studies (rs2768744 and rs2814778).
Use of rs2814778 as a Surrogate for Ancestry at the
1q23.2 Locus
The ‘‘C’’ allele of rs2814778 (also ‘‘FY2’’) is known to be almost
completely correlated to West African ancestry at the chromosome
1q23.2 locus. We therefore used this allele as a marker to study the
epidemiological association of African ancestry to various WBC
phenotypes (Figure 1 and Tables 1 and 2). In addition to using
FY2 as a surrogate for ancestry, in the final analyses of this study
(Figure 3 and Table 4), we took advantage of the fact that the
correlation between this allele and African ancestry, though
.99%, is not perfect. Thus, we could test whether the allele is
more predictive of neutrophil count than is African ancestry itself.
Testing Other Leukocyte Counts after Controlling for the
Effect of Neutrophil Count
To test for association of the chromosome 1 locus to counts of
leukocytes other than neutrophils, we carried out a regression
analysis between absolute counts of neutrophils and absolute
counts of each of the other white blood cell types. This generated a
residual value for each cell type after correcting for the effect of
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of each of these residuals to carrier status for European ancestry at
the chromosome 1 locus (defined as having at least one FY+ allele
at rs2814778), using Z-scores to indicate the difference, in
standard deviations, in the population means between groups of
samples. These Z scores can be approximately translated into a P-
value by referring to the corresponding percentile in the
cumulative normal distribution function.
Narrowing the Chromosome 1 Peak by Admixture
Mapping
The ANCESTRYMAP software [11] was used to better define the
region of chromosome 1 associated to neutrophil count. Since the
software is optimized for dichotomous traits, we divided the 6,005
samples into 12 strata (with 399–593 samples each) based on their
normally transformed neutrophil counts (Table 3). For each stratum,
we identified arisk model(increased probability ofobserving a sample
with 1 or 2 copies of European ancestry compared with the
expectation from the genome-wide average) that optimized the peak
LOD score at the locus. This ranged from a 25-fold decrease in the
relative probability of European ancestry for individuals with
neutrophil counts ,21.5 standard deviations below the mean, to a
6.5-fold increase for those with neutrophil counts .1.5 standard
deviations above the mean. For each stratum, the risk model and
LOD score at the chromosome 1 locus are given in Table 3.
To use these strata to define an admixture peak, we carried out an
admixture scan for each group separately, and then summed the
LOD scores at loci interpolated every tenth of a centimorgan. The
peak LOD score was 363.1 as shown in Table 3. The 99% credible
interval of 155.957–156.408 Mb in Build 35 of the human genome
reference sequence was determined by the region where the score
was within log10(e
6.63/2)=1.44 of its maximum (Figure 2). This is
calculated from a likelihood ratio test, using the fact that a x
2 statistic
with 1 degree of freedom of 6.63 corresponds to P=0.01.
Testing for an Association of rs2814778 above and
beyond the Admixture Association
To assess whether genotype at rs2814778 is more predictive of
neutrophil count than ancestry, we calculated two numbers for each
DNA sample. First, we recorded whether the individual was a carrier
of the FY+ ‘‘functional’’ allele (=1) at rs2814778, or was homozygous
for the FY2 ‘‘null’’ allele (=0) (homozygosity for the ‘‘null’’ allele
abolishesexpressionoftheDuffyantigenonredbloodcellsbutnoton
other cell types). Second, we used the ANCESTRYMAP software
[11] to estimate the probability that in the region spanning this SNP,
at least one of the individual’s chromosomes was of European
ancestral origin. Importantly, we included the genotype of rs2814778
in the ancestry estimation. Thus, if neutrophil count were better
correlated to rs2814778 genotype than to an ancestry estimate that
included information from both rs2814778 and closely neighboring
SNPs, it would indicate that the neighboring SNPs did not add
relevant information, and that rs2814778 is either the causal variant
or is in strong LD with the causal variant.
To determine whether genotype at rs2814778 or ancestry at the
chromosome 1 locus was the better predictor of neutrophil status,
we carried out three regressions:
(a) We regressed the genotype of the Duffy functional allele at
rs2814778 to neutrophil count under a dominant model and
calculated a x
2 statistic.
(b) We regressed inferred European ancestry at the chromo-
some 1 locus to neutrophil count using a dominant model
and calculated a x
2 statistic.
(c) We regressed both predictors together to neutrophil count
and calculated a x
2 statistic.
Totestforevidenceofanassociation ofthegenotype atrs2814778
above and beyond ancestry, we subtracted the x
2 statistics of (c)-(b).
To test for evidence of association to ancestry above and beyond
SNP genotype, we subtracted the x
2 statistics of (c)-(a).
Case-Control Fine-Mapping Over the Admixture Peak in
JHS Samples
To test whether there were SNPs apart from rs2814778 that
contributed evidence for association at the chromosome 1 locus,
we densely genotyped a subset of especially informative samples.
To select cases and controls for fine-mapping, we identified
individuals from JHS for whom we were .99% confident of
African ancestry on both chromosomes at the admixture peak. By
limiting cases and controls to persons with more confident
estimates of entirely African local ancestry, it was easier to detect
whether any signal of association was significant above and
beyond the admixture association. For this analysis, the estimate of
ancestry at the admixture peak using ANCESTRYMAP [11]
excluded SNPs within the peak.
Among individuals who had .99% confidence of entirely African
ancestry at the locus, we identified 696 individuals who had a ‘‘low’’
neutrophil count, defined based on visual inspection of the
distribution as an absolute count of ,2,100/mm
3 (and correspond-
ing to ,0.7 s.d. below the population mean for the entire JHS
sample). We also identified 77 individuals who had a ‘‘high’’
neutrophil count, defined as an absolute count of 5,100/mm
3–
9,100/mm
3 (1.3–2.8 s.d. above the population mean). For
genotyping, we selected a random subset of individuals with ‘‘low’’
neutrophil count, and all of the individuals with ‘‘high’’ neutrophil
count. We successfully genotyped 148 subjects with low and 74
subjects with high neutrophil count that we could use inthis analysis.
To identify additional SNPs across the admixture peak that
might be associated with neutrophil levels, we used the Tagger
software [12] to choose a panel of SNPs from the International
Haplotype Map database [10] that captured all SNPs of .5%
minor allele frequency in West African samples with a correlation
of r
2.0.8. Forcing these SNPs into the analysis, we chose
additional SNPs across the region until we had similarly captured
all SNPs in European Americans with .5% minor allele
frequency. All SNPs identified in this way were selected for
genotyping on the Sequenom iPLEX platform [43]. Cases and
controls were successfully genotyped at a densely spaced panel of
193 tag SNPs across the ,450 kilobase admixture peak. Each SNP
was tested using a x
2 statistic assuming an additive effect on
neutrophil count for each additional copy of the allele. We did not
test a dominant or recessive model because none of the genotyped
SNPs (apart from rs2814778) had a frequency differentiation
across populations consistent with that SNP explaining the
admixture signal (and thus being the main effect SNP; see above).
We chose an additive model to search for variants that might
modulate the neutrophil count beyond the main effect because it is
known that for substantial minor allele frequencies this provides
reasonable power to detect an association, whether the true
underlying effect is dominant, additive, or recessive [44].
Analysis of Shotgun Sequencing Data to Rule out the
Great Majority of Nucleotides in the Admixture Peak as
Containing the Causal Allele
While we found that rs2814778 was more predictive of
neutrophil count than ancestry, we were concerned that the
variant might not itself be causal, but instead only in LD with the
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region that are highly different in frequency between Africans and
Europeans, we examined shotgun genome sequence data derived
from public databases, from 6 individuals who were known to have
West African ancestry across the region (NA18507, NA18517,
NA19129, NA19240, NA17109 and NA17119), and 5 individuals
who were known to have European ancestry across the region
(NA12156, NA12878, NA07340, HuAA and HuBB). These
sequences include 4 West Africans and 2 Europeans examined as
partof a fosmidend-sequencingproject[45], 2 EuropeanAmericans
sequenced as part of the Celera Genomics human genome
sequencing project [46,47], 1 European American sequenced for
the purpose of SNP discovery [48,49], and 2 African Americans also
sequenced for SNP discovery [48,49], who we determined had
entirelyAfrican ancestryat thelocus byusing the ANCESTRYMAP
software [11] and by unpublished methods (Simon Myers, Alkes
Price and Alon Keinan, personal communication). For each
individual, we only analyzed nucleotides for which we had a high
quality base call at the locus (Neighborhood Quality Score of $40)
[13]. At sites where we had more than 16coverage, we randomly
sampled one sequence to represent the individual.
To determine the ancestry of the human genome reference
sequence across the admixture peak, we first observed that it was
spanned by a mosaic of 5 fully sequenced Bacterial Artificial
Chromosomes (BACs), each representing a clone of 86,000–
196,000 base pairs (http://genome.ucsc.edu). The problem of
determining ancestry of the human reference sequence across the
region thus amounts to determining the ancestry of each of the
clones separately. To do this, we obtained the allele of the human
genome reference sequence at each of 284 HapMap SNPs across
the region that had been genotyped in both West Africans and
European Americans. For each window of 8 consecutive SNPs in
HapMap, we calculated the likelihood that the human reference
sequence was of African or European ancestry. To determine this
likelihood empirically, we compared the findings to 120 phased
European chromosomes and 120 phased African chromosomes
from the HapMap database, counting the number of matches to
the human reference sequence in each population over that
window. We conservatively added 1 to the counts of the tested
haplotype for each population to preclude an estimate of zero
probability for either population. Under the assumption that only
European and African ancestry were possible, the results showed
with confidence that 3 of the clones were of European ancestry
and 2 were of African ancestry (Figure 4).
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